Ensoma, a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system, agreed to acquire Twelve Bio, a gene editing company. Financial terms were not disclosed. “The development of groundbreaking genetic medicines to cure complex diseases and reach the largest population of patients is a challenge. At Twelve Bio, we have developed innovative gene editing tools that can correct sequences linked to genetic disorders, and Ensoma is a world-leading company for in vivo delivery to hemopoietic stem cells. I am very excited about working together, and I am confident we will be able to bring forward innovative single-dose medicines to cure life-threatening diseases,” Stefano Stella, Twelve Bio Director and Chief Technology Officer.